A precision medicine approach to metabolic therapy for breast cancer in mice

Mice with breast cancer driven by mutations upstream of the PI3K/Akt insulin signaling pathway are found to be responsive to dapagliflozin, while those driven by mutations downstream of PI3K/Akt or in pathways with other driver mutations did not.

Bibliographic Details
Main Authors: Ngozi D. Akingbesote, Aaron Norman, Wanling Zhu, Alexandra A. Halberstam, Xinyi Zhang, Julia Foldi, Maryam B. Lustberg, Rachel J. Perry
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-022-03422-9